Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis.

Zhou Y, Yuan Y, Cai RR, Huang Y, Xia WQ, Yang Y, Wang P, Wei Q, Wang SH.

Expert Opin Pharmacother. 2013 Aug;14(12):1575-84. doi: 10.1517/14656566.2013.810210. Epub 2013 Jul 5.

PMID:
23826679
2.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I.

Lancet. 2010 Feb 27;375(9716):735-42. doi: 10.1016/S0140-6736(09)61965-6. Epub 2010 Feb 16.

PMID:
20167359
3.

Colesevelam for type 2 diabetes mellitus.

Ooi CP, Loke SC.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009361. doi: 10.1002/14651858.CD009361.pub2. Review.

PMID:
23235674
4.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

5.

Continuous glucose monitoring systems for type 1 diabetes mellitus.

Langendam M, Luijf YM, Hooft L, Devries JH, Mudde AH, Scholten RJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008101. doi: 10.1002/14651858.CD008101.pub2. Review.

PMID:
22258980
6.

Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus.

Zhang L, Gong D, Li S, Zhou X.

Atherosclerosis. 2012 Jul;223(1):78-85. doi: 10.1016/j.atherosclerosis.2012.01.031. Epub 2012 Jan 23. Review.

PMID:
22326029
7.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

8.

Time to initiation of oral antihyperglycemic and statin therapy in previously untreated patients with type 2 diabetes in the United States.

Sun P, Tunceli K, Zhang Q, Seck T, Iglay K, Davies MJ, Ambegaonkar B, Radican L.

Curr Med Res Opin. 2013 Jul;29(7):801-6. doi: 10.1185/03007995.2013.800473. Epub 2013 May 10.

PMID:
23621515
9.

Statins for women with polycystic ovary syndrome not actively trying to conceive.

Raval AD, Hunter T, Stuckey B, Hart RJ.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD008565. doi: 10.1002/14651858.CD008565.pub2. Review.

PMID:
21975784
10.

Prognostic factors for successful insulin therapy in subjects with type 2 diabetes.

Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, Menheere PP.

Neth J Med. 1999 Feb;54(2):63-9.

PMID:
10079680
11.

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA; Simvastatin/Thiazolidinedione Study Group.

Clin Ther. 2004 Mar;26(3):379-89.

PMID:
15110130
12.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
13.

Lower intensified target LDL-c level of statin therapy results in a higher risk of incident diabetes: a meta-analysis.

Cai R, Yuan Y, Zhou Y, Xia W, Wang P, Sun H, Yang Y, Huang R, Wang S.

PLoS One. 2014 Aug 14;9(8):e104922. doi: 10.1371/journal.pone.0104922. eCollection 2014.

14.

The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.

Sun YN, Zhou Y, Chen X, Che WS, Leung SW.

BMJ Open. 2014 Apr 7;4(4):e004619. doi: 10.1136/bmjopen-2013-004619. Review.

15.
16.

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140. Review.

17.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
18.
19.

Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.

Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD003287. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD003287.

PMID:
15495047
20.

Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.

Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR.

Cochrane Database Syst Rev. 2004;(2):CD003287. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD003287.

PMID:
15106199
Items per page

Supplemental Content

Write to the Help Desk